Filing Details
- Accession Number:
- 0001209191-19-012247
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-21 18:06:11
- Reporting Period:
- 2019-02-19
- Accepted Time:
- 2019-02-21 18:06:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750019 | Tcr2 Therapeutics Inc. | TCRR | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1687078 | Mpm Oncology Impact Management Lp | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
| 1691428 | L.p. Fund Impact Oncology Ubs | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
| 1721035 | Mpm Oncology Impact Management Gp Llc | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
| 1721036 | L.p. Management (Cayman) Fund Impact Oncology | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-19 | 2,421,775 | $0.00 | 2,421,775 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2019-02-19 | 282,540 | $0.00 | 2,704,315 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2019-02-19 | 666,667 | $15.00 | 3,370,982 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2019-02-19 | 15,000,000 | $0.00 | 2,421,775 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-02-19 | 1,750,000 | $0.00 | 282,540 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- All shares of Series A Preferred Stock and Series B Preferred Stock automatically converted into the number of shares of the Issuer's common stock on a 6.1938:1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
- The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC.
- The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
Billionaire Hedge Funds
